Published • loading... • Updated
Alzheimer’s Treatment Has Changed. Has Value?
Summary by avalerehealth.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Alzheimer’s Treatment Has Changed. Has Value?
A New Treatment Era and a New Set of Questions Treatment for Alzheimer’s disease (AD) is entering a new phase. After decades of stalled progress, two new disease-modifying therapies have emerged. Anti-amyloid monoclonal antibodies (mAbs), lecanemab and donanemab, have received regulatory approvals in the US and several jurisdictions in Europe, the Middle East, Africa, and the Asia-Pacific region, with additional reviews ongoing globally. For the…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
